NEWS DESK

TIL Stock News, News Score & What It Could Mean

Instil Bio, Inc. - Common Stock (TIL) is currently showing a bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently positive earnings tone.

HEADLINE TAKE: Higher-value headlines lean clearly negative, with stronger signals around downgrades, warnings, weak results, or other pressure points.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
31/100
Bearish
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$7.62
Trend Context
Mixed / range
Latest briefing

What's happening with TIL

globenewswire.com1 Jun 2026

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com15 May 2026

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 202…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Earnings news

TIL earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your TIL research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK